Although systemic onset juvenile idiopathic arthritis (SJIA) treatment has evolved thanks to targeted medications, a sizable portion of patients with the rare condition are resistant to the new drugs. Still, not everyone benefits from the new treatments. Approximately 1 in 7 patients will not respond to treatment. Additional disease-modifying anti-rheumatic medications can be used to […]